CYP2D6 metabolism and patient outcome in the Austrian breast and colorectal cancer study group trial (ABCSG) 8

Clinical Cancer Research

Volumn 19, Issue 2, 2013, Pages 500-507

  Goetz, Matthew P ^a   Suman, Vera J ^a   Hoskin, Tanya L ^a   Gnant, Michael ^b   Filipits, Martin ^b   Safgren, Stephanie L ^a   Kuffel, Mary ^a   Jakesz, Raimund ^b   Rudas, Margaretha ^b   Greil, Richard ^c   Dietze, Otto ^c   Lang, Alois ^d   Offner, Felix ^d   Reynolds, Carol A ^a   Weinshilboum, Richard M ^a   Ames, Matthew M ^a   Ingle, James N ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d Medical Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CYP2D6 GENE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 84872580456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2153     Document Type: Article

References (31)

1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28: 509-18.
2. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28: 3784-96.
3. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy- N -desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85: 151-9.
4. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95: 1758-64.
5. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310: 1062-75.
6. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97: 30-9.
7. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011;89: 718-25.
8. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011;89: 708-17.
9. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010;70: 854-69.
10. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23: 9312-8.
11. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302: 1429-36.
12. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010;28: 2768-76.
13. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifentreated breast cancer patients. J Natl Cancer Inst 2012;104: 452-60.
14. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012;104: 441-51.
15. Brauch HB, Schroth W, Ingle JN, Goetz MP. CYP2D6 and tamoxifen: awaiting the denouement. J Clin Oncol 2011;29: 4589-90.
16. Dahabreh I, Terasawa T, Castaldi P, Trikalinos TA. CYP2D6 testing to predict response to tamoxifen in women with breast cancer: pharmacogenomic. PLoS Curr 2010;2:RRN1176.
17. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausalwomen with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-62.
18. Castells A, Gusella JF, Ramesh V, Rustgi AK. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 2000;60: 2836-9.
19. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 2001;7: 876-82.
20. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine- responsive early breast cancer from the Austrian breast and colorectal cancer study group. J Clin Oncol 2012;30: 722-8.
21. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25: 2127-32.
22. Bergstralh E, Kosanke J. Computerized matching of cases to controls. Rochester, MN: Department of Health Science Research, Mayo Clinic; 1995.
23. Rosenbaum PR. Optimal matching for observational studies. JASA 1989;84: 1024-32.
24. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Practice/Am Soc Clin Oncol 2010;6: 243-6.
25. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.
26. Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2012;131: 455-61.
27. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011; 103: 489-500.
28. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52.
29. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48: 943-50.
30. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353: 487-97.
31. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109: 832-9.